Last reviewed · How we verify

Acrux DDS Pty Ltd — Portfolio Competitive Intelligence Brief

Acrux DDS Pty Ltd pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Testosterone MD-Lotion Testosterone MD-Lotion phase 3 Androgen replacement therapy Endocrinology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abbott · 1 shared drug class
  2. Acerus Pharmaceuticals Corporation · 1 shared drug class
  3. Alliance for Clinical Trials in Oncology · 1 shared drug class
  4. Bayer · 1 shared drug class
  5. Beersheva Mental Health Center · 1 shared drug class
  6. Clarus Therapeutics, Inc. · 1 shared drug class
  7. Imperial College Healthcare NHS Trust · 1 shared drug class
  8. Laboratoires Besins International · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Acrux DDS Pty Ltd:

Cite this brief

Drug Landscape (2026). Acrux DDS Pty Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/acrux-dds-pty-ltd. Accessed 2026-06-10.

Related